Blood glucose levels were determined at 0 h, 0.5 h, 1 h, 1.5 h, and 2 h after injection of LPS or NS with an Accu-chek glucometer (Roche, Mannheim, Germany) from tail-bled samples (made with a needle stick).
All BG measurements were made using bedside glucometers (AccuChek Inform, Almere, The Netherlands) and arterial blood; capillary blood was never used.
All BG measurements were made by using bedside glucometers (AccuChek Inform; Roche, Almere, The Netherlands) and arterial blood.
Health promoters were also provided with glucometers so they could test patient's glucose at the sessions in the hope that this would also encourage attendance.
After randomization, all subjects were asked to check their fasting capillary blood glucose concentrations at least once every other day with glucometers (Accu-Chek Performa, Roche, Basel, Switzerland).
Some patients do self-monitoring with glucometer but it is not accurate – he does not know how to use it properly.
A baseline blood glucose measurement (0 min) was made using a standard glucometer.
Fasting blood glucose was determined using commercial glucometer made by accu-chek.
In addition, BG levels were measured with glucometer (HemoCue Glucose 201 DM, HemoCue AB. Ängelholm, Sweden) to obtain BG measurements every 30 min.
Current CGMS technology measures glucose concentrations in interstitial fluid, which are highly correlated with glucometer-derived plasma-corrected glucose measures (34, 35).
